Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | HTR1A | P08908 | 8/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.50 |
| ▸ | HTR1D | P28221 | 6/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29445402 | 1.00 | CA2 (0.52) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL8510380 | 0.90 | CA2 (0.50) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL3641960 | 0.89 | CYP1A2 (0.51) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL12064816 | 0.87 | CYP1A2 (0.54) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL6051185 | 0.86 | CA2 (0.55) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL14271049 | 0.86 | CA2 (0.55) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL8935402 | 0.83 | CA2 (0.52) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL8935393 | 0.83 | CA2 (0.52) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL407503 | 0.83 | CA2 (0.56) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL8599906 | 0.83 | CA2 (0.52) | CA2HTR1ASIGMAR1ADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9617597-B2 | Genetic susceptibility variants associated with cardiovascular disease | DECODE GENETICS EHF (IS) | 2017-04-11 | — | — | US | disclosed |
| US-8158362-B2 | Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype | DECODE GENETICS EHF. (IS) | 2012-04-17 | — | — | US | disclosed |
| US-7838533-B2 | Azaindole inhibitors of MTP and ApoB | MERCK PATENT GMBH (DE) | 2010-11-23 | — | — | US | disclosed |
| US-20100216863-A1 | Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment | DECODE GENETICS EHF. (IS) | 2010-08-26 | — | — | US | disclosed |
| US-20100120045-A1 | GENETIC VARIANTS USEFUL FOR RISK ASSESSMENTS OF CORONARY ARTERY DISEASE AND MYOCARDIAL INFARCTION | DECODE GENETICS EHF (IS) | 2010-05-13 | — | — | US | disclosed |
| US-20100068705-A1 | GENETIC SUSCEPTIBILITY VARIANTS ASSOCIATED WITH CARDIOVASCULAR DISEASE | DECODE GENETICS EHF (IS) | 2010-03-18 | — | — | US | disclosed |
| US-20090036481-A1 | Novel Azaindole Inhibitors of Mtp and Apob | MERCK PATENT GMBH (DE) | 2009-02-05 | — | — | US | disclosed |
| US-20080293750-A1 | Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment | DECODE GENETICS EHF. (IS) | 2008-11-27 | — | — | US | disclosed |
| US-20070280917-A1 | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment | DECODE GENETICS, INC. (IS) | 2007-12-06 | — | — | US | disclosed |
| US-20060019269-A1 | Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment | DECODE GENETICS, INC. (IE) | 2006-01-26 | — | — | US | disclosed |
| US-20050272051-A1 | Methods of preventing or treating recurrence of myocardial infarction | DECODE GENETICS EHF. (IS) | 2005-12-08 | — | — | US | disclosed |
| US-5925662-A | OXIDASE INHIBITORS | SYNTHELABO (FR) | 1999-07-20 | — | — | US | disclosed |
| EP-0859776-A1 | COMPOUNDS DERIVED FROM OXAZOLIDIN-2-ONE AND PREPARATION AND THERAPEUTICAL USE THEREOF | SYNTHELABO (FR) | 1998-08-26 | — | — | EP | disclosed |
| WO-1997017347-A1 | COMPOUNDS DERIVED FROM OXAZOLIDIN-2-ONE AND PREPARATION AND THERAPEUTICAL USE THEREOF | SYNTHELABO (FR) | 1997-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120045-A1 | GENETIC VARIANTS USEFUL FOR RISK ASSESSMENTS OF CORONARY ARTERY DISEASE AND MYOCARDIAL INFARCTION | TNNI3, TSG101, ALDH1B1 | CA2 2460/4885HTR1A 2049/4885SIGMAR1 4265/4885 |
| US-20090036481-A1 | Novel Azaindole Inhibitors of Mtp and Apob | APOB, MTPN, HDLBP | CA2 4883/4885HTR1A 1619/4885SIGMAR1 3262/4885 |
| US-20100216863-A1 | Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment | ALOX15B, ALOX15, ALOX5 | CA2 4585/4885HTR1A 1015/4885SIGMAR1 4724/4885 |
| US-20070280917-A1 | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment | ALOX15B, ALOX15, ALOX5 | CA2 4585/4885HTR1A 1015/4885SIGMAR1 4724/4885 |
| US-20080293750-A1 | Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment | PLAAT3, PLAAT2, PLA2G7 | CA2 3479/4885HTR1A 1697/4885SIGMAR1 4864/4885 |
| US-20060019269-A1 | Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment | PLAAT3, PLAAT2, PLA2G7 | CA2 3721/4885HTR1A 1504/4885SIGMAR1 4851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.